Intensity Therapeutics Inc. (INTS)
(Delayed Data from NSDQ)
$0.28 USD
+0.01 (3.70%)
Updated Oct 3, 2025 04:00 PM ET
After-Market: $0.28 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Fundamental Charts
About Return on Equity (TTM)
Intensity Therapeutics Inc.'s return on equity, or ROE, is -612.44% compared to the ROE of the Medical - Biomedical and Genetics industry of -65.07%. While this shows that INTS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
INTS 0.28 +0.01(3.70%)
Will INTS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for INTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INTS
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
INTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INTS
Crossed Above 50 Day Moving Average appears for INTS after 3.7% move
Is INTS preparing to trend higher? Crossed Above 50 Day Moving Average shows up after rocketing 8.15%
Is INTS primed for upward momentum? Crossed Above 20 Day Moving Average shows up after rallying 6.22%
Technical picture remains unchanged for INTS after it falls 1.1% on September 30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session